490
Views
16
CrossRef citations to date
0
Altmetric
Review

Tryptase inhibitors: a patent review

, , , &
Pages 919-928 | Received 10 Jan 2017, Accepted 19 Apr 2017, Published online: 03 May 2017
 

ABSTRACT

Introduction: Tryptase is one of the main serine-proteinases located in the secretory granules of mast cells, and is released through degranulation, which is involved in the pathogenesis of allergic inflammatory disease, cardiovascular diseases, lung fibrosis and tumor. Therefore, inhibitors targeting tryptase may represent a new direction for the treatment of allergic inflammatory disease and other diseases.

Areas covered: In this article, we discussed the history and development of tryptase inhibitors and described a variety of tryptase inhibitors via their structures and biological importance in clinical studies and drug development for tryptase-related diseases.

Expert opinion: Initial tryptase inhibitors based on indole structure as the hydrophobic substituent on a benzylamine-piperidine template have low specificity and poor bioavailability. Therefore, designing new and specific inhibitors targeting tryptase should be involved in future clinical studies. Modifications toward indoles with varying N-substitution, introducing an amide bond, and growing the chain length contribute to an increase in the specific selectivity and potency of tryptase inhibitors. Tryptase has become the research hotspot to explore many related diseases. Therefore, there has been growing appreciation for the potential importance of the tryptase inhibitors as a target for treating these diseases.

Article highlights

  • This paper summarized the structures, biological importance and clinical trials of tryptase inhibitors, and pointed out the development direction of these tryptase inhibitors.

  • Several initial tryptase inhibitors that have been evaluated in preclinical models of asthma have significant drawbacks. So, much effort has been directed toward the identification and synthesis of a variety of new low molecular weight compounds with potential inhibitory activity and appropriate selectivity toward tryptase.

  • Among the various groups of tryptase inhibitors, guanidino-based tryptase inhibitors are the most potent and hold the most potential for clinical use in inflammatory diseases.

  • Clinical trials of tryptase inhibitor were focused on inflammatory diseases.

  • Tryptase inhibitors have become the research hotspot to explore other tryptase-related diseases, such as hepatic fibrosis and tumor. However, it needs more clinical trials to go to market.

This box summarizes key points contained in the article.

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This study was sponsored by grants from the National Natural Science Foundation of China (nos. 81571568, 31340073 and 81273274); Jiangsu Province’s Key Provincial Talents Program (no. RC201170); the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,757.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.